FDA Re-evaluates 'Dietary Substance' Definition: Innovation vs. Regulation
The US FDA is reviewing its 'dietary substance' definition, potentially broadening regulatory pathways for novel ingredients derived from plant cell culture and precision fermentation. This re-evaluation could either spur supplement innovation or increase compliance burdens, depending on public health safeguarding measures.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington D.C., United States — 31 March 2026
The US Food and Drug Administration (FDA) is actively reconsidering the definition of 'dietary substance' under the Dietary Supplement Health and Education Act (DSHEA). This review is driven by rapid advancements in ingredient manufacturing technologies, specifically plant cell culture and precision fermentation, which are producing novel compounds currently challenging existing regulatory frameworks.
Discussions at a recent public forum highlighted a divergence between industry and consumer groups. Industry representatives advocate for an expanded definition to accommodate scientific progress and foster innovation, suggesting that a narrower interpretation restricts the integration of new, potentially beneficial ingredients. Conversely, consumer protection advocates voice concerns regarding public health implications, urging caution against loosening definitions without robust safety assurances.
The FDA is examining whether 'dietary substance' should remain confined to ingredients historically present in the food supply or if it should be widened to include these scientifically advanced, novel materials. Critical to this debate are the pathways for new ingredients, particularly the interplay between Generally Recognized As Safe (GRAS) self-affirmations and New Dietary Ingredient (NDI) notifications. A clearer delineation or integration of these processes is sought to reduce ambiguity and streamline market entry for valid innovations.
Transparency in labelling and robust safety evaluation protocols were also key discussion points, underscoring the FDA’s dual mandate of promoting innovation while protecting public health. The agency has initiated a 30-day public comment period to gather further stakeholder input, signalling an intent to formulate policy that balances these objectives.
What this means for United States
US manufacturers and brand owners face a critical juncture. A broader definition of 'dietary substance' could unlock significant innovation opportunities, allowing unique ingredients developed through advanced bio-manufacturing to enter the market. This could lead to a competitive advantage with novel product formulations. However, a redefinition will likely necessitate updated compliance strategies, potentially including revised NDI submission criteria and stricter data requirements for GRAS filings. Brands should closely track FDA communications for new guidance, assess their existing and pipeline ingredient portfolios against potential shifts, and prepare for possible reformulation windows or revised substantiation costs. Engagement in the public comment period is vital for shaping the regulatory outcome and ensuring industry operational continuity.
The discussions addressed the regulatory pathways for new ingredients, the intersection of GRAS and New Dietary Ingredient Notifications, and the need for transparency and clarity in labeling and safety evaluations.
The outcome will impact product development timelines and investment in new ingredient research and development, necessitating strategic planning for market entry and sustained compliance.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.